SGLT-2 inhibitors have emerged as a key treatment for patients with T2DM and CKD, and more recently, SGLT-2 inhibitors have become a main therapeutic pillar in the management of patients with HF, regardless of their LVEF. The gene discussed is SLC5A2; the disease is hydrops fetalis.